best of the best

3 Houston employers clock in among Fortune's 100 best companies to work

Three Houston companies have been recognized for their superior work environments. Getty Images

Hunting for a job in Houston? A new ranking from Fortune magazine suggests you might consider three local companies.

Camden Property Trust, David Weekley Homes, and Hilcorp Energy Co. all rank on Fortune's 2020 list of the 100 Best Companies to Work For, published February 18.

Fortune bases its annual list of the best workplaces on a nationwide study done by analytics firm Great Place to Work. This time around, the study featured input from more than 4.1 million U.S. workers who responded to over 60 survey questions.

Houston-based apartment owner and operator Camden Property Trust comes in at No. 18, an improvement over last year's rank of 19. The real estate owner and operator is known for a lighthearted corporate culture that has seen executives willing to poke fun at themselves and others at company events and celebrations, according to the list.

Camden Property Trust continues to be one of Houston's best places to work. Camden Property Trust/Facebook

There are also perks to working for an apartment landlord; 44 percent of employees live in Camden-owned apartments and take advantage of a 20 percent rent-discount benefit that collectively saves them more than $1.9 million per year.

Not far down the list, at No. 23, is Houston-based homebuilder David Weekley Homes, which makes a big leap over last year's rank of 41. Family comes first at this nationwide homebuilding company, says the report. Prospective employees often participate in Key Influencer Visits, where they are interviewed (often in their homes) alongside family members or close friends to help hiring managers better understand their personalities and backgrounds.

There's also an internship program designed specifically for employees' children and a discount on homes sold to staffers and their family members (a set percentage based on tenure). One worker says, "It really exemplifies how the company puts the employees first, even before customers."

New to the list this year is Houston-based oil and gas production company Hilcorp Energy Co. The largest privately held oil and natural-gas production company in the U.S., Hilcorp challenges its employees to think in terms of Big Hairy Audacious Goals, the lofty performance goals it sets every five years. For every BHAG met, employees are rewarded with significant cash bonuses and even new cars.

To meet these goals, CEO Greg Lalicker believes, total transparency is a must, from frontline employees to the CFO, according to the report. All financials, cash flow, investments, oil- and gas-price impacts, BHAG progress reports, and other critical information are shared in monthly, companywide "lifting cost" meetings. "It blows your mind to be in your first lifting-cost meeting and hear supersecret information," recalls one new hire.

Five other Texas-based employers also appear on this year's list:

  • No. 15. - Arlington-based Texas Health Resources ranks first among Texas-based employers and 15th nationwide on Last year, the organization ranked ninth nationwide.
  • No. 55. - San Antonio-based financial services provider USAA. Last year's rank: 30.
  • No. - 66. Dallas-based Ryan LLC, a provider of tax software and services. Last year's rank: 52.
  • No. 86. - San Antonio-based oil pipeline and terminal operator NuStar Energy LP. Last year it was unranked.
  • No. 88. - Dallas-based Encompass Health Home Health & Hospice, part of Birmingham, Alabama-based Encompass Health Corp. Last year's rank: 54.

Nationwide, McLean, Virginia-based Hilton Worldwide Holdings Inc. ranks first on this year's Fortune list, followed by Weston, Florida-based Ultimate Software Group Inc., Rochester, New York-based Wegmans Food Markets Inc., San Jose, California-based Cisco Systems Inc., and Pleasanton, California-based Workday Inc.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News